Access to payers is about knowledge, about understanding what they do in their jobs
Should pharma formulate a super matrix to determine the FMV of research incentives?
Pharmaceutical companies must provide robust marketing support for their clinical trials
A new industry has emerged to provide analytics and predictive tools that support optimized care
Pharma can be in the moment with customers as they interact with our information or products
Big Data is coming and with it the danger of pharmaceutical marketers relying on it too heavily
In 2014, the "new healthcare marketing" will become more discontinuous from the old
As I pull out my crystal ball, I see a day where we WANT to use secondary research first
The next generation of drugs sees a number of market access challenges
A quiet revolution is underway in research to keep pace with changes in medical marketing
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.